Multiple active pharmaceutical ingredient production lines of Xinxiang Pharmaceutical, a wholly-owned subsidiary of Tuoxin Pharmaceutical, have passed a drug GMP compliance inspection. The company announced on July 28 that Xinxiang Pharmaceutical received a Drug GMP Compliance Inspection Notification issued by the Henan Medical Products Administration, covering production lines for inosine, ribavirin, acyclovir, and vidarabine monophosphate, all of which comply with the requirements of the Good Manufacturing Practice for Drugs (2010 Revision). The inspection was conducted from June 6 to June 8, 2026. In the first quarter of 2026, Tuoxin Pharmaceutical achieved revenue of 92.5 million yuan and a net loss attributable to the parent company of 10.51 million yuan.
Xinxiang Tuoxin Pharmaceutical Co.Ltd.Subsidiary's API production lines passed GMP compliance inspection, enabling continued operation.
Received Drug GMP Compliance Inspection Notification for multiple API lines.